Mirum Pharmaceuticals Inc

NASDAQ:MIRM   10:14:07 AM EDT
15.90
+0.11 (+0.70%)
Products

Mirum Pharmaceuticals Announces FDA Acceptance Of New Drug Application And Priority Review For Maralixibat In Alagille Syndrome

Published: 03/29/2021 14:37 GMT
Mirum Pharmaceuticals Inc (MIRM) - Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome.
Mirum Pharmaceuticals Inc - PDUFA Action Date is September 29, 2021.
Mirum Pharmaceuticals Inc - FDA Has Indicated That Advisory Committee is Not Currently Planned.